# 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

August 14, 2026 7:47 PM EDT

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026.

**Financial Highlights for the Quarter Ended June 30, 2026:**

- Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
- Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 2025.
- Operating expenses were approximately $2.33 million for the second quarter of 2026, compared with approximately $1.86 million for the second quarter of 2025.
- Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, for the second quarter of 2026, compared with a net loss of approximately $1.84 million, or $5.01 per share, for the second quarter of 2025.

Additional information regarding the Company's results is available in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

**About 60 Degrees Pharmaceuticals, Inc.**

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.



Media Contact:
Kristen Landon
kristenlandon@60degreespharma.com

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com

Sixty Degrees Pharma